Orionis Biosciences Announces First Patient Dosed in Phase 1 Clinical Trial of ORB-011 in Patients with Advanced Solid Tumors

BOSTON & GHENT, Belgium--(BUSINESS WIRE)--Orionis Biosciences, a life sciences company pioneering the creation of highly selective and tunable therapeutics for cancer and other diseases, today announced that the first patient has been dosed in a Phase 1 clinical trial of ORB-011, an attenuated, cis-targeted interferon immunotherapy based on the company’s A-Kine® platform. ORB-011 is the first clinical candidate to emerge from the platform, which engineers cytokines to be highly selective for sp